Sharescart Research Club logo
Products
Research
Tools
About
  • Home
  • /
  • Kilpest India
ChatGPT Claude Perplexity
Summarize with
ChatGPT Claude Perplexity
Join Channel

3B Blackbio Dx

WEBSITE BSE:532067 NSE: 3BBLACKBIO Inc. Year: 1972 Industry: Medical Equipment/Supplies/Accessories My Bucket: Add Stock

₹1322.4 25 | 1.9%

Last updated: 15:57

Consolidated Standalone

Last updated: 15:57

3B Blackbio Dx Overview

Kilpest India Ltd is an totally agri-based business enterprise. The Company on the whole offers agrochemicals. The Company's agriculture business includes crop safety products and public health products, bio products, micro-vitamins and mix fertilizers. The Company gives chemical merchandise, which include pesticides, which include Bheem, Karfu, Frutofix, Kilzex D, Kildon, Pradhan and Shock; anti-bacterial products, along with Kiltomycin; fungicides, including Kiltaf, Micfun, Pearl, Ajomil and Blast; herbicides/weedicides, such as Stump, Chapet...Read More

Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

3B Blackbio Dx Key Financials

Market Cap ₹1135 Cr.

Stock P/E 23.8

P/B 3.5

Current Price ₹1322.4

Book Value ₹ 373.6

Face Value 10

52W High ₹2019.9

Dividend Yield 0.3%

52W Low ₹ 1110

Edit Ratio

3B Blackbio Dx Share Price

₹ | |

Volume
Price

3B Blackbio Dx Quarterly Price

Quarterly Monthly
Show Value Show %

3B Blackbio Dx Peer Comparison

3B Blackbio Dx Quarterly Results

#(Fig in Cr.) Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025
Net Sales 19 18 23 19 29 25 22 22 34 50
Other Income 3 3 4 4 3 3 5 4 6 6
Total Income 22 20 27 23 33 28 27 27 39 56
Total Expenditure 11 9 13 8 13 10 15 10 19 29
Operating Profit 11 12 14 15 20 18 13 16 20 27
Interest 0 0 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 0 0 0 0 1 0
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 10 11 14 14 19 18 13 16 20 27
Provision for Tax 3 3 5 3 4 4 5 3 5 4
Profit After Tax 8 9 9 11 15 13 8 13 15 22
Adjustments 0 0 0 -0 -0 -0 0 -0 -0 -1
Profit After Adjustments 8 9 9 11 15 13 8 13 15 22
Adjusted Earnings Per Share 9.2 10.2 10.4 13 17.1 15.6 9.8 14.7 17.2 25.4

3B Blackbio Dx Profit & Loss

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 19 17 16 23 23 29 227 81 62 74 96 128
Other Income 0 0 0 0 1 2 3 7 7 13 15 21
Total Income 19 17 16 23 24 30 230 88 69 87 112 149
Total Expenditure 18 16 14 18 16 20 77 44 33 41 46 73
Operating Profit 1 2 3 6 8 11 153 44 36 46 65 76
Interest 1 1 1 1 0 0 0 0 0 0 0 0
Depreciation 0 0 0 0 1 1 1 1 1 1 1 1
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 0 0
Profit Before Tax 0 0 1 5 7 10 152 43 35 44 64 76
Provision for Tax 0 0 0 1 2 2 38 11 9 12 16 17
Profit After Tax 0 0 1 3 5 8 114 32 26 32 48 58
Adjustments 0 0 0 0 0 -0 0 0 0 0 0 -1
Profit After Adjustments 0 0 1 3 5 8 114 32 26 32 48 58
Adjusted Earnings Per Share 0.6 0.7 1.8 5.4 8.2 10.2 152 43 30.3 37.5 55.7 67.1

Growth Rates

# 1 Year 3 Year 5 Year 10 Year
Sales CAGR 30% 6% 27% 18%
Operating Profit CAGR 41% 14% 43% 52%
PAT CAGR 50% 14% 43% 0%
# 1 Year 3 Year 5 Year 10 Year
Share Price CAGR -26% 45% 24% 64%
ROE Average 19% 17% 42% 28%
ROCE Average 26% 22% 55% 35%

3B Blackbio Dx Balance Sheet

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 10 10 11 18 23 32 132 153 193 223 268
Minority's Interest -0 -0 0 0 0 2 16 19 3 2 3
Borrowings 2 3 3 2 2 1 1 1 1 1 0
Other Non-Current Liabilities 1 1 1 1 1 1 1 2 3 4 6
Total Current Liabilities 12 10 11 9 10 8 43 17 14 18 19
Total Liabilities 25 24 26 30 36 45 194 192 214 248 296
Fixed Assets 4 3 3 4 4 4 5 7 8 7 7
Other Non-Current Assets 0 0 0 0 0 2 70 104 92 117 156
Total Current Assets 21 21 22 26 32 39 118 82 114 123 132
Total Assets 25 24 26 30 36 45 194 192 214 248 296

3B Blackbio Dx Cash Flow

#(Fig in Cr.) Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 0 0 0 0 2 9 35 29 59 62
Cash Flow from Operating Activities 0 1 1 2 4 7 98 37 20 27 43
Cash Flow from Investing Activities -0 -0 -0 -1 -1 -1 -70 -28 15 -20 -34
Cash Flow from Financing Activities -0 -1 -0 0 -1 1 -2 -15 -5 -4 -3
Net Cash Inflow / Outflow -0 0 0 1 2 7 26 -6 30 3 6
Closing Cash & Cash Equivalent 0 0 0 2 2 9 35 29 59 62 69

3B Blackbio Dx Ratios

# Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0.56 0.69 1.77 5.37 8.2 10.25 152 42.98 30.28 37.46 55.66
CEPS(Rs) 0.82 1.16 2.48 6.08 9.06 10.98 152.82 43.88 31.28 38.7 56.93
DPS(Rs) 0 0 0.3 0.5 0.5 0.7 1 10.5 2.5 3 4
Book NAV/Share(Rs) 15.84 16.33 17.57 21.4 35.2 42.87 176.27 204.26 225.6 260.32 313.27
Core EBITDA Margin(%) 6.53 8 14.76 23.17 31.02 32.27 66.15 46 47.08 44.49 51.94
EBIT Margin(%) 5.53 6.46 13.71 22.4 31.85 35.97 67.15 53.73 57.42 59.98 66.45
Pre Tax Margin(%) 1.45 2.32 8.04 19.28 29.86 34.81 67.05 53.6 57.1 59.81 66.34
PAT Margin (%) 1.13 1.78 6.51 14.63 22.52 26.62 50.22 39.93 41.94 43.31 49.44
Cash Profit Margin (%) 2.56 3.94 9.12 16.58 24.87 28.48 50.49 40.76 43.34 44.73 50.56
ROA(%) 0.96 1.37 4.55 12.22 15.71 18.94 95.54 16.7 12.77 13.89 17.54
ROE(%) 2.33 3.26 10.47 27.55 28.99 28.15 138.73 22.59 14.98 15.42 19.41
ROCE(%) 6.6 6.8 12.52 23.8 28.04 32.29 179.46 29.92 20.24 21.21 26.03
Receivable days 233.78 261.7 290.63 239.28 274.14 242.8 44.04 146.56 188.65 172.8 137.66
Inventory Days 71.7 70.01 76.56 59.84 67.94 57.29 7.2 27.85 45.68 40.55 32.48
Payable days 192.18 188.74 0 113.29 124.67 100.56 22.43 37.45 70.42 61.16 42.09
PER(x) 14.62 11.45 19.45 24.9 9.21 7.08 1.87 7.94 13.73 20.54 29.05
Price/Book(x) 0.52 0.48 1.96 6.25 2.14 1.69 1.62 1.67 1.84 2.96 5.16
Dividend Yield(%) 0 0 0.87 0.37 0.66 0.96 0.35 3.08 0.6 0.39 0.25
EV/Net Sales(x) 0.66 0.71 1.87 3.86 2.19 1.68 0.79 2.84 4.83 8.07 13.65
EV/Core EBITDA(x) 8.68 7.61 10.69 15.7 6.41 4.44 1.18 5.21 8.22 13.14 20.2
Net Sales Growth(%) -13.71 -8.4 -6.72 43.61 0.28 24.05 685.26 -64.43 -23.32 19.87 30.14
EBIT Growth(%) 0.22 6.92 95.73 120.31 41.33 40.08 1366.08 -71.54 -18.05 25.2 44.2
PAT Growth(%) -38.62 43.46 238.01 202.69 52.99 46.66 1381.27 -71.72 -19.45 23.77 48.56
EPS Growth(%) -39.67 22.2 157.19 202.57 52.81 24.95 1383.24 -71.72 -29.55 23.74 48.56
Debt/Equity(x) 0.74 0.74 0.78 0.42 0.28 0.11 0.02 0.02 0.01 0 0
Current Ratio(x) 1.81 1.98 2.05 3.03 3.08 4.82 2.76 4.82 8.05 7.04 7.11
Quick Ratio(x) 1.47 1.66 1.68 2.61 2.6 4.32 2.64 4.38 7.49 6.56 6.64
Interest Cover(x) 1.35 1.56 2.42 7.19 16.02 31.08 666.83 407.23 178.97 357.08 590.84
Total Debt/Mcap(x) 1.42 1.53 0.39 0.07 0.13 0.06 0.01 0.01 0.01 0 0

3B Blackbio Dx Shareholding Pattern

# Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Promoter 38.43 41.29 41.29 41.29 41.29 41.28 41.28 41.28 41.28 40.94
FII 3.38 2.97 3.28 3.27 2.68 2.49 2.7 2.64 2.57 2.57
DII 1.18 1.89 1.96 1.96 1.74 1.6 1.76 1.82 1.88 1.98
Public 57 53.85 53.48 53.49 54.29 54.63 54.26 54.26 54.28 54.51
Others 0 0 0 0 0 0 0 0 0 0
Total 100 100 100 100 100 100 100 100 100 100

3B Blackbio Dx News

3B Blackbio Dx Pros & Cons

Pros

  • Company has delivered good profit growth of 43% CAGR over last 5 years
  • Debtor days have improved from 61.16 to 42.09days.
  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Promoter holding is low: 40.94%.
  • Stock is trading at 3.5 times its book value.

* The pros and cons are machine generated.

You May Also Know About

Unlisted Shares Pre-IPO Shares ESOP Shares Delisted Shares
whatsapp

Please Login!

Click to Login
OR
Get free Account

Error!